As an approach to the rational design of combination chemotherapy involving the anti-cancer DNA topoisomerase II poison etoposide (VP-16), we have studied the dynamic changes occurring in small-cell lung cancer (SCLC) cell populations during protracted VP-16 exposure. Cytometric methods were used to analyse changes in target enzyme availability and cell cycle progression in a SCLC cell line, mutant for the tumour-suppressor gene p53 and defective in the ability to arrest at the GI/S phase boundary. At concentrations up to 0.25 gmM VP-16, cells became arrested in G2 by 24 h exposure, whereas at concentrations 0.25-2 iLM G. arrest was preceded by a dose-dependent early S-phase delay, confirmed by bromodeoxyuridine incorporation. Recovery potential was determined by stathmokinetic analysis and was studied further in aphidicolinsynchronised cultures released from GI/S and subsequently exposed to VP-16 in early S-phase. Cells not experiencing a VP-16-induced S-phase delay entered G, delay dependent upon the continued presence of VP-16. These cells could progress to mitosis during a 6-24 h period after drug removal. Cells experiencing an early S-phase delay remained in long-term G2 arrest with greatly reducing ability to enter mitosis up to 24 h after removal of VP-16. Irreversible G2 arrest was delimited by the induction of significant levels of DNA cleavage or fragmentation, not associated with overt apoptosis, in the majority of cells. Western blotting of whole-cell preparations showed increases in topoisomerase II levels (up to 4-fold) attributable to cell cycle redistribution, while nuclei from cells recovering from S-phase delay showed enhanced immunoreactivity with an anti-topoisomerase Ila antibody. The results imply that traverse of G,/S and early S-phase in the presence of a specific topoisomerase II poison gives rise to progressive low-level trapping of topoisomerase IIE, enhanced topoisomerase availability and the subsequent irreversible arrest in G2 of cells showing limited DNA fragmentation. We suggest that protracted, low-dose chemotherapeutic regimens incorporating VP-16 are preferentially active towards cells attempting G,/S transition and have the potential for increasing the subsequent action of other topoisomerase II-targeted agents through target enzyme modulation. Combination modalities which prevent such dynamic changes occurring would act to reduce the effectiveness of the VP-16 component.
As an approach to the rational design of combination chemotherapy involving the anti-cancer DNA topoisomerase II poison etoposide (VP-16), we have studied the dynamic changes occurring in small-cell lung cancer (SCLC) cell populations during protracted VP-16 exposure. Cytometric methods were used to analyse changes in target enzyme availability and cell cycle progression in a SCLC cell line, mutant for the tumour-suppressor gene p53 and defective in the ability to arrest at the GI/S phase boundary. At concentrations up to 0.25 gmM , cells became arrested in G2 by 24 h exposure, whereas at concentrations 0.25-2 iLM G. arrest was preceded by a dose-dependent early S-phase delay, confirmed by bromodeoxyuridine incorporation. Recovery potential was determined by stathmokinetic analysis and was studied further in aphidicolinsynchronised cultures released from GI/S and subsequently exposed to VP-16 in early S-phase. Cells not experiencing a VP-16-induced S-phase delay entered G, delay dependent upon the continued presence of VP-16. These cells could progress to mitosis during a 6-24 h period after drug removal. Cells experiencing an early S-phase delay remained in long-term G2 arrest with greatly reducing ability to enter mitosis up to 24 h after removal of VP-16. Irreversible G2 arrest was delimited by the induction of significant levels of DNA cleavage or fragmentation, not associated with overt apoptosis, in the majority of cells. Western blotting of whole-cell preparations showed increases in topoisomerase II levels (up to 4-fold) attributable to cell cycle redistribution, while nuclei from cells recovering from S-phase delay showed enhanced immunoreactivity with an anti-topoisomerase Ila antibody. The results imply that traverse of G,/S and early S-phase in the presence of a specific topoisomerase II poison gives rise to progressive low-level trapping of topoisomerase IIE, enhanced topoisomerase availability and the subsequent irreversible arrest in G2 of cells showing limited DNA fragmentation. We suggest that protracted, low-dose chemotherapeutic regimens incorporating VP-16 are preferentially active towards cells attempting G,/S transition and have the potential for increasing the subsequent action of other topoisomerase II-targeted agents through target enzyme modulation. Combination modalities which prevent such dynamic changes occurring would act to reduce the effectiveness of the VP-16 component. etoposide) , a semisynthetic derivative of the naturally occumrng antimitotic agent podophyllotoxin, has become established as one of the most active agents in the treatment of small-cell lung cancer (SCLC) . Preclinical studies have provided evidence of schedule dependency (Dombernowsky & Nissen, 1973; Wolfe et al., 1987) and the critical importance of a prolonged schedule has been confirmed in man by Slevin et al. (1989a,b) . It has been suggested that continuous low concentrations of VP-16 are required for optimal activity of the drug when administered as a single agent (Clark et al., 1989) , and very prolonged schedules of oral VP-16 have been evaluated and found to be effective (Hainsworth et al., 1989; Clark et al., 1990 Clark et al., , 1991 Einhorn et al., 1990; Johnson et al., 1990) . Since druginduced, persistent cytostasis is an important clinical goal for the control of rapidly proliferating tumours, we have studied the dose dependency and kinetics of processes leading to irreversible cell cycle arrest of SCLC cells to VP-16 following protracted exposure in vitro.
VP-16 appears to initiate its cytotoxic action by acting as a specific poison for the cell cycle-regulated protein DNA topoisomerase II (Heck et al., 1988; Liu, 1989) . DNA topoisomerase II is a nuclear enzyme that effects unknotting, decatenation or relaxation of supercoiled DNA molecules by a process of introducing transient double-strand breaks through which the strands of an intact helix can pass (Wang, 1985) . Topoisomerase poisoning results in the trapping of enzyme molecules on DNA as cleavable complexes and the subsequent generation of potentially lethal lesions (Glisson & Ross, 1987; Liu, 1989 VP-16 (Miller et al., 1990) . The intrinsic sensitivity of actively proliferating tumour cells to topoisomerase II poisons appears to depend in part on the availability of the target enzyme (Liu, 1989; Smith & Makinson, 1989) . The major type II enzyme, topoisomerase Ila, is cell cycle regulated, and as such its availability increases as cells progress towards mitosis (Heck et al., 1988) . Thus, protracted VP-16 exposure would be expected to modulate the availability of the target enzyme as a result of changes in cell cycle progression. The study is pertinent to the use of low levels of VP-16 in the control of tumour growth since changes in the expression of topoisomerase II may play a central role in the inhibition of cell cycle transit (Lock & Ross, 1990) , the development of drug resistance associated with low levels of target enzyme and in defining chemosensitivity to other agents used in combination regimens.
The responses of tumour cells to topoisomerase poisoning are not dependent upon topoisomerase gene expression alone. There appears to be a requirement for the p53 protooncogene-encoded protein both in the efficient activation of apoptosis and in cell cycle arrest following exposure to DNA-damaging anti-cancer agents or acute irradiation (Livingstone et al., 1992; Clarke et al., 1993; Lowe et al., 1993) . The p53 protein appears to act as an element in the operation of a G1/S checkpoint (Kastan et al., 1992; Lane, 1992) , whereby the induction of DNA damage causes the half-life of the protein to increase, preventing S-phase entry and blocking the replication of damaged DNA. However, somatic mutation of the p53 locus is a frequent occurrence in human tumours (HolUstein et al., 1991) , with small-cell lung cancer showing one of the highest rates of p53 mutation (Takahashi et al., 1989 (Takahashi et al., , 1991 Levine et al., 1991) . Cancers with p53 mutations tend to respond to chemotherapy more weakly than those showing wild-type alleles (Callahan, 1992 Cell cycle analysis and detection of mitotic subpopulations
Cells were stained with ethidium bromide (50igml'1) plus 0.125% Triton X-100 and ribonuclease (0.5pgml-') for 10 min prior to analysis. DNA fluorescence distributions were analysed by a computer using a cell cycle phase-fitting program, which assumes normal distributions for GI and G2/M phase populations (Watson et al., 1987) . A probability function was calculated for the S-phase distribution based upon the means and standard deviations of the GI and G2/M phases. For stathmokinetic experiments, VP-16-treated and control cultures were exposed to colmid (60 ng ml') in order to induce mitotic arrest and low-scatter mitotic populations were analysed as described previously (Epstein et al., 1988) .
DNA strand breakage in single cells with respect to cell cycle position The technique depends upon accurate measurements of the fluorescence intensities (corresponding to cellular DNA content) and volumes (corresponding to the extent of DNA damage-induced unwinding of nuclear DNA) of nuclei denatured in agarose gels (Smith & Sykes, 1992 and held for 30 min at room temperature. Finally, cells were pelleted and resuspended in PBS containing propidium iodide (at a final concentration Sjgml-') to stain nuclear DNA. Subsequent analysis and the use of fluorescence controls has been described previously (Karn et al., 1989) .
SDS polyacrylamide gel electrophoresis and Western blotting
Briefly, whole-cell lysates were prepared by direct lysis of cells in hot (65'C) sample buffer (1.0 ml of 0.5 M Tris-Cl, pH 6.8, 0.8 ml of glycerol, 1.6 ml of 10% SDS, 0.4 ml of 2-mercaptoethanol, 0.2 ml of 0.05% bromophenol blue in 8 ml final volume) at a concentration of I x I0ocells 100 #1l'.
Lysates were boiled for 10 min, forced through a 21-gauge needle four times to shear the DNA, and spun at 13,000r.p.m. in an Eppendorf centrifuge. The supernatant was retained and 10#il loaded directly onto acrylamide gels (7.5% acrylamide with a stacking gel of 4% acrylamide). In the subsequent studies the effects of low (0.25 jLM) and high (2 gM) dose levels of VP-16 were compared. At the low dose level, maximum G2 arrest is observed at 24 h without significant S-phase delay. On the other hand, 2 1M VP-16 allows maximal G, emptying but induces significant S-phase delay during the first 24 h exposure.
Stathmokinetic analysis of cell cycle delay and recovery Using the mitotic spindle inhibitor colcemid, it was possible to investigate further the cell cycle perturbations caused by VP-16 without the complications of cell division and resupply of G,. Analysis of bivariate plots of right-angle scatter and DNA content of cells permitted the identification of a low light scatter population (LSP) in G2 representing cells entering mitosis (Epstein et al., 1988) . The colemid exposure of H69 cells was staggered to follow the number of cells attempting mitosis (i.e. escaping the G2 delay induced by VP-16) in the presence of VP-16 or after release into VP-16-free medium (Table I ). The discrimination between G2 and M populations is not absolute (Epstein et al., 1988) Table I Figure 3a DNA damage as a function of cell cycle position We have used an adaptation of the 'comet' assay (Singh et al., 1988; Smith & Sykes, 1992) to detect DNA breakage resulting from cleavage of trapped topoisomerase complexes or secondary fragmentation events as monitored by the nucleoid volume measurements. Figure 4 a VP-16-induced changes in topoisomerase II availability Whole population studies Immunoblots of whole-cell preparations of H69 cultures exposed to VP-16 for 24 h showed a major immunoreactive band with a mean molecular weight (± s.d. for ten determinations) of 171.3 ± 2.9 kDa corresponding to that expected for the p170 form of human DNA topoisomerase IIa. An increase in the intensity of the p170 band above control was observed for all VP-16-treated samples, and densitometry ( Figure 5 ) was used to quantify the changes with respect to control samples. The p170 band intensity increased with drug dose and exposure period, reaching a maximum of 3.7-fold at doses of l-2 M VP-16 with a reduction in band intensity evident at 8 LM VP-16.
Single-cell analysis and cell cycle distribution To relate the cell cycle perturbations to the changes in topoisomerase lIIK we have utilised a flow cytometric technique (Smith & Makinson, 1989) (Smith et al., 1986) , lymphoblasts (Kalwinsky et al., 1983) and breast tumour cells (Epstein et al., 1988 Smith, unpublished data) . The lack of early induction of apoptosis is not surprising since it has been reported that SCLC cell lines may differ in their ability to express VP-16-induced apoptosis (Okamoto-Kubo et al., 1994) and the potential requirement of functional p53 for efficient induction (Clarke et al., 1993; Lowe et al., 1993) . Additional studies are required to determine whether the damage visualised by nucleoid scanning represents target enzyme trapping or a secondary process of preapoptotic, perhaps DNA domain-limited, fragmentation.
We suggest that the minimal cytotoxic dose threshold for low-dose, protracted VP-16 exposures is defined by the dose intensity required to impose an early S-phase delay rather than effect G2 arrest per se. In the in vivo situation, the maintenance of a low but bioactive drug concentration would allow the continued recruitment of tumour cells into S-phase delay as they opt to enter the cell cycle since it is unlikely that the G,, S checkpoint is functional in SCLC and GI emptying is not affected even by high drug doses. It is evident that SCLC cells can overcome the initial restriction to early S-phase traverse even in the continued presence of VP-16 and cells eventually enter a G, delayed state with enhanced availability of topoisomerase II.
Clinical studies have supported the concept that prolonged low-dose VP-16 treatment offers the combined benefits of efficacy and low toxicity. On the other hand, it is clear that such treatment will not break new ground in terms of increasing response duration or survival either when used alone (Slevim et al., 1989a,b) or as part of a conventionally designed regimen (Murphy et al., 1992) . However, prolonged schedules of VP-16 treatment may be a foundation for novel combination regimens which capitalise on the consequences of continuous topoisomerase II poisoning such as cell cycle synchronisation or modulation of topoisomerase II levels. This hypothesis was evaluated by exposing H69 cells to VP-16 for 24 h prior to treating washed cultures with selected agents and assaying growth potential using the conventional MTT assay (data not shown). The results indicated that VP-16 pretreatment results in a greater than 2-fold enhancement of growth inhibition potential for cisplatin, Amsacrine (mAMSA) and VP-16, while the other agents (camptothecin, mitoxantrone and doxorubicin) gave values of less than 1.3-fold enhancement.
The absence of an effect on sensitivity to the topoisomerase I poison camptothecin is consistent with the non-cell cycle-regulated nature of the target enzyme (Heck et al., 1988) . VP-16 pretreatment did not interfere with the cytotoxic potential of the topoisomerase poisons doxorubicin and mitoxantrone, suggesting that the initial capacity to induce topoisomerase II cross-linking not being an important factor in the cytotoxic action of anthracyclines and related drugs Smith et al., 1990) . The >2-fold enhancement of cytotoxicity observed for the topoisomerase II poisons mAMSA and VP-16 is itself consistent with the effects of topoisomerase II modulation. The observations of enhanced cisplatin sensitivity is interesting given the capacity of this agent to induce DNA-DNA and DNA-protein cross-linking in what may be topologically compromised DNA molecules in VP-16-pretreated cells.
The implications for cancer chemotherapy are that dynamic changes in cell cycle distribution and target enzyme presentation in tumour cells exposed for protracted periods to low doses of VP-16 may offer novel opportunities for the introduction of other agents in combined regimens. The single-cell analytical approach described here offers a method of monitoring the effects of chronic VP-16 exposure in vivo within defined tumour target populations.
